Overview

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Status:
Not yet recruiting
Trial end date:
2023-07-10
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the PK of apraglutide in subjects with hepatic impairment compared with matched control subjects with normal hepatic function following single SC dose administration.
Phase:
Phase 1
Details
Lead Sponsor:
VectivBio AG